Utility of plasma tumour necrosis factor-alpha and transforming growth factor-beta1 as predictors of survival and treatment outcome in advanced non-small cell lung carcinoma.
We hypothesized that plasma level of tumour necrosis factor (TNF)-alpha and transforming growth factor (TGF)-beta1 may be a potential tool for diagnosis, prognosis and prediction of treatment outcome in non-small cell lung carcinoma (NSCLC). Plasma levels of TNF-alpha and TGF-beta1 were quantified in 100 NSCLC patients and 100 controls. Association of TNF-alpha and TGF-beta1 with response to therapy and survival was determined in 42 patients. An increased presence of TNF-alpha and TGF-beta1 was observed in NSCLC compared with controls. TNF-alpha and TGF-beta1 levels did not correlate with survival and response to chemotherapy. TNF-alpha and TGF-beta1 do not appear to be reliable markers for predicting survival and response to therapy in advanced NSCLC.
Kumar
Sachin
S
Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Guleria
Randeep
R
Mohan
Anant
A
Singh
Vikas
V
Ali
Ashraf
A
Bharti
Alok C
AC
Das
Bhudev C
BC
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D053773:Transforming Growth Factor beta1 / Q000097:blood*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*
D014408:Biomarkers, Tumor; D053773:Transforming Growth Factor beta1; D014409:Tumor Necrosis Factor-alpha